Vyndaqel found most effective in early-stage FAP in real world: Study
Among familial amyloid polyneuropathy (FAP) patients carrying the most common FAP-causing mutation Val30Met, treatment with Vyndaqel (tafamidis meglumine) is most effective when given at the very early stages of the disease. That’s according to the findings of a real-world study in Spain, which linked a cutoff value of…